Site Search
* Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07) ** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development o
Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07) ** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)
Department: Oncology
Diagnosis: Cancer - Oncology
A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Title: A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Cancer - Lung
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2 Advanced Breast Cancer (OPERA-02)
Title: A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant with Ribociclib Versus Letrozole with Ribociclib for the First-Line Treatment of ER+, HER2 Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
A Prospective, Multi-Center, Non-Randomized, SinGle-Arm Study of the BDTM Low ProfILe Vascular Covered Stent in PerIpheral ArTerY Disease (AGILITY)
Title: A Prospective, Multi-Center, Non-Randomized, SinGle-Arm Study of the BDTM Low ProfILe Vascular Covered Stent in PerIpheral ArTerY Disease (AGILITY)
Department: Vascular Surgery
Diagnosis: Vascular Disease
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: THE RESTORATIVE303 STUDY
Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: THE RESTORATIVE303 STUDY
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or witho
Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Department: Oncology
Diagnosis: Cancer - Oncology
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients with End-Stage Renal Disease
Title: A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients with End-Stage Renal Disease
Department: Vascular Surgery
Diagnosis: Vascular Disease
A032102, PREcision DIagnostics in prostate Cancer Treatment (PREDICT)
Title: A032102, PREcision DIagnostics in prostate Cancer Treatment (PREDICT)
Department: Oncology
Diagnosis: Cancer - Oncology
ALLIANCE A222004: A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA
Title: ALLIANCE A222004: A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA
Department: Oncology
Diagnosis: Cancer - Oncology